Potential biomarkers for adult acute myeloid leukemia minimal residual disease assessment searched by serum peptidome profiling.

ABSTRACT:

Background

Post treatment minimal residual disease (MRD) determination contributes to impending relapse prediction, chemotherapy response and clinical outcomes assessment, guiding clinicians to develop reasonable and effective individual chemotherapy options after induction/consolidation. This study was to identify serum candidate peptides for monitoring adult acute myeloid leukemia (AML) MRD.

Results

47 statistically different expressed peptide peaks were obtained in the molecular weight range of 700-10000 Da. Quick classifier (QC) model had optimal distinction efficiency, in the training set with a sensitivity of 90% and a specificity of 93.33%. Peptides were identified as ubiquitin-like modifier activating enzyme 1(UBA1), isoform 1 of fibrinogen alpha chain precursor and

SUBMITTER: Bai J 

PROVIDER: S-EPMC3751134 | biostudies-literature | 2013

REPOSITORIES: biostudies-literature